Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 8-K (Current Report)
Date of Report: October 12, 2022
Event: Completion of a public offering of Units consisting of common stock and warrants.
Key Financial Metrics
This filing reports on a capital raise event rather than operational financial performance. Specific metrics include:
- Gross Proceeds: $5,100,000.30
- Units Sold: 3,777,778
- Offering Price: $1.35 per Unit
- Underwriter: WallachBeth Capital LLC
Note: The filing does not provide data on revenue, profit, operating cash flow, margins, or existing debt levels.
Material Changes and Offering Structure
The primary material change is the issuance of new equity and warrants. Each Unit sold includes:
- One share of common stock ($0.001 par value).
- One Series A Warrant: Exercise price $1.62 (120% of offering price).
- One Series B Warrant: Exercise price $1.35 (100% of offering price).
- One Series C Warrant: Exercise price $2.16 (160% of offering price).
All warrants are exercisable for five years. The Series C Warrants include a cashless exercise provision if the VWAP of the common stock fails to exceed the exercise price within specific volume and time parameters.
Over-Allotment: The underwriters were granted a 45-day option for up to 566,666 additional shares/warrants. The representative exercised this option for 556,037 Purchase Warrants.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard terms of the warrant agreements. The offering was made pursuant to a registration statement on Form S-1 declared effective on October 6, 2022.
Investor Verification Checklist
- Verify the total number of shares outstanding post-offering to assess dilution.
- Confirm the exercise of the over-allotment option for the 556,037 additional warrants.
- Review the specific cashless exercise triggers for Series C Warrants in the event of low stock volume or price.
- Check the use of proceeds in subsequent filings to ensure alignment with stated capital needs.